US Oncology Network

The US Oncology Network reached a major milestone recently in its journey to provide high-quality, value-based care to local communities by enrolling its 100,000th patient in the Centers for Medicare & Medicaid Innovation’s (CMMI) Oncology Care Model (OCM)

COVID-19 has created a significant distraction from normal practice operations. The uncertainty that comes along with the pandemic is a huge worry, and can distract from practice transformation.

The authors, from RxCrossroads by McKesson, discuss the impact of copay accumulator and maximizer programs.

As health care costs rise, especially for patients with complex conditions, a major barrier to access is the disconnect between medical benefits and pharmacy benefits.

Available in patients’ own communities, novel clinical trials are making an impact in the fight against cancer.

Gavreto was granted accelerated approval by the FDA on September 4, 2020, for the treatment of adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC).

Inqovi was approved by the FDA on July 7, 2020, for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).

The CDC is exercising an option of an existing contract with McKesson for this effort.